Game-changing data published in the New England Journal of Medicine and presented during the 2018 ASCO Annual Meeting indicated that many women with HR+, HER2–, axillary node–negative breast cancer would see no significant benefit to having chemotherapy in addition to endocrine therapy.
Game-changing data published in the New England Journal of Medicine and presented during the 2018 ASCO Annual Meeting indicates that many women with hormone-receptor (HR)—positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node–negative breast cancer would see no significant benefit to having chemotherapy in addition to endocrine therapy.
Standard treatment of this subgroup of women with breast cancer has traditionally used a recurrence score (based on a 21-gene breast cancer assay) to determine if a woman should receive endocrine therapy alone or endocrine therapy plus chemotherapy. Women at low risk of recurrence (<10) typically received endocrine therapy alone while those at high risk (>25) received the combination therapy. The problem was that there was uncertainty about how women with a midrange recurrence score of 11-25 should be treated.
A large group of researchers led by Joseph Sparano, MD, from Albert Einstein College of Medicine in Bronx, NY, conducted a prospective trial called TAILORx, involving 9719 women with HR—positive, HER2–negative, axillary node–negative breast cancer. In this group, 6711 (69%) with a midrange recurrence score of 11-25 were randomly assigned to receive either endocrine therapy alone or endocrine therapy plus chemotherapy.
At 9 years, the endocrine-therapy group and the endocrine therapy plus chemotherapy group had similar rates of invasive disease—free survival (DFS; 83.3% vs. 84.3%, respectively), freedom from disease recurrence at a distant site (94.5% vs. 95%, respectively) or at a distant or local–regional site (92.2% vs. 92.9%, respectively), and overall survival (93.9% vs. 93.8%, respectively). The chemotherapy benefit for invasive DFS varied with the combination of recurrence score and age, with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16-25.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.